The content on this site is intended for healthcare professionals only
Dr Sandra Swain speaks to ecancer about her talk at this year’s virtual BGICC.
She says that her lecture this year is about HER2 advanced breast cancer and recent therapies regarding it.
She then speaks about some of the recent targeted therapies that have been proven by clinical trials to be effective against HER2 positive breast cancer.
Dr Swain explains the data obtained form these studies and what it implied. In the end, she mentions some of the older approved drugs that are also effective against this type of cancer and future studies can be built up on those as well.
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Saruparib shows encouraging efficacy and safety in mutant advanced solid tumours
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer
Adding ribociclib to endocrine therapy shows an improvement in invasive disease-free survival in HR+/HER2 BC patients
CodeBreaK 200 shows sotorasib to be a more tolerable treatment option for patients with pretreated, KRASG12C-mutated advanced NSCLC
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
Hypofractionated high dose intensity modulated radiotherapy non-inferior for prostate cancer
Loco-regional management after neoadjuvant chemotherapy
Elacestrant shows improved PFS in ER-positive/HER2-negative mBC
